Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives

Around 4% of advanced non-small-cell lung cancers (NSCLCs) have an ALK rearrangement at the time of diagnosis. This molecular feature is more frequent in young patients, with no/light smoking habit and with adenocarcinoma pathological subtype. Crizotinib is a tyrosine kinase inhibitor, targeting ALK...

Descripción completa

Detalles Bibliográficos
Autores principales: Leprieur, Etienne Giroux, Fallet, Vincent, Cadranel, Jacques, Wislez, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310701/
https://www.ncbi.nlm.nih.gov/pubmed/28210164
http://dx.doi.org/10.2147/LCTT.S99303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310701/
https://www.ncbi.nlm.nih.gov/pubmed/28210164
http://dx.doi.org/10.2147/LCTT.S99303

Ejemplares similares